9,446 reports of this reaction
3.7% of all RISPERIDONE reports
#3 most reported adverse reaction
ABNORMAL WEIGHT GAIN is the #3 most commonly reported adverse reaction for RISPERIDONE, manufactured by Janssen Pharmaceuticals, Inc.. There are 9,446 FDA adverse event reports linking RISPERIDONE to ABNORMAL WEIGHT GAIN. This represents approximately 3.7% of all 254,329 adverse event reports for this drug.
RISPERIDONE has an overall safety score of 85 out of 100. Patients taking RISPERIDONE who experience abnormal weight gain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ABNORMAL WEIGHT GAIN is moderately reported among RISPERIDONE users, representing a notable but not dominant share of adverse events.
In addition to abnormal weight gain, the following adverse reactions have been reported for RISPERIDONE:
The following drugs have also been linked to abnormal weight gain in FDA adverse event reports:
ABNORMAL WEIGHT GAIN has been reported as an adverse event in 9,446 FDA reports for RISPERIDONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ABNORMAL WEIGHT GAIN accounts for approximately 3.7% of all adverse event reports for RISPERIDONE, making it one of the most commonly reported side effect.
If you experience abnormal weight gain while taking RISPERIDONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.